EUROPEAN CITIZENS PERCEPTION - SURVEY 2021 Report
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
EUROPEAN CITIZENS PERCEPTION SURVEY 2021 Report
European Citizens Perception Survey
EXECUTIVE SUMMARY
Never before has the role and importance of public health been at the forefront of public debate. The opportunity to implement the learnings from the COVID-19
pandemic and ensure Europe’s Pharmaceutical Strategy creates a competitive, world-class system for innovation for patients in Europe comes at a critical
time. Both the perceptions and expectations of European citizens will inform this debate and the policy choices to be made on the future of healthcare in Europe.
To assess the perceptions of European citizens on areas central to future healthcare policy in Europe, Lilly carried out a survey in late 2020 of the general public
in 14 European countries (Belgium, Bulgaria, Czechia, France, Germany, Hungary, Ireland, Italy, the Netherlands, Poland, Portugal, Romania, Slovenia and Spain).
We looked at six key areas:
1. The impact of the pandemic on the perception of the biopharmaceutical industry (page 3)
2. Public awareness of the scale and scope of research and development (R&D) in the biopharmaceutical industry (page 5)
3. Opinions on levels of access to medicines (page 10)
4. Priorities in healthcare (page 15)
5. Opportunities presented by digital health (page 18)
6. Opinions on the environmental performance of the biopharmaceutical industry (page 20)
The first iteration of this report was published in 2019 with six countries featured: Belgium, France, Germany, Ireland, Italy and Spain.
The results from this initial survey will be referred to throughout as the ‘2019 Survey’. Certain questions from the 2019 Survey have
been repeated in the 2020 Survey, allowing us to draw comparisons regarding how opinions have changed over time. It is important
to bear in mind that these results and comparisons are applicable only to the six countries that were represented in the 2019 Survey.
To read more about our policy recommendations to make life better for patients and support the EU in being a world leader in life
sciences, including learnings to date from COVID-19, visit www.LillyEU.com.
1European Citizens Perception Survey
SNAPSHOT OF KEY FINDINGS
The biopharmaceutical industry is likely to guess this (11%), and people in Slovenia were the least likely (3%).
viewed more favourably since the start
of the pandemic. This small but Europeans surveyed were twice as likely to believe the US was the fastest
significant shift has likely been due to market for medicines approval. In 2019, it took a median of 423 days for the
the role biopharmaceutical companies European Medicines Agency (EMA) to approve a new active substance
have played in developing COVID-19 versus 243 days in the USA.2
vaccines and treatments, as well as an
increased appreciation of the role of the Respondents were more likely to be pessimistic than optimistic about their
healthcare system in society more own country’s speed and level of access in comparison with other EU
generally. countries, and more than half of respondents would prioritise faster access
to medicine, even if that meant higher purchase costs.
Europeans surveyed were 2-4 times more likely to correctly answer that the
biopharmaceutical industry is the one that invests the largest percentage of Europeans surveyed identified cancer as their top health priority for the next
its income in R&D in the EU.¹ Though the biopharmaceutical industry was the five years, followed by cardiovascular disease and respiratory diseases.
most popular answer, an overall majority still assume that it is another Alzheimer’s disease and dementia fell out of the top 3 to fifth priority.
industry that invests most, such as aerospace and defence, software and
computer services, or the automotive sector. Most Europeans remain open to providing health data to support digital
innovation in healthcare, but there is a trend towards less comfort in doing
Respondents on average believed 33% of medicines are made available to so. Respondents in Hungary and France are the most likely to be
patients after entering clinical trials. Only 10% of medicines successfully uncomfortable with sharing data in this way (37% and 35%). Those in
make it through clinical trials. Those in Slovenia were the most likely to Bulgaria, Poland and Italy are the most likely to be comfortable with this
correctly estimate that 1-24% of medicines successfully make it through (74%, 73% and 71%).
clinical trials (40%), and those in France were the least likely (26%).
Europeans identify the biopharmaceutical industry as a top performer in
Respondents estimated that just over one third of Active Pharmaceutical environmental efforts. Portuguese respondents were the most likely to rank
Ingredients (APIs) for new medicines are developed in the EU. More than three the pharmaceutical industry among the top 3 industries for environmental
quarters of APIs are developed in the EU. People in Romania were the most efforts (32%), while Dutch respondents were the least likely (11%).
1. Mafini et al (European Commission, Joint Research Centre). The 2020 EU industrial R&D investment scoreboard. 2020. 2. Centre for Innovation in Regulatory Science. R&D Briefing 77. 2020.
DOI: 10.2760/203793 URL: https://cirsci.org/wp-content/uploads/2020/06/CIRS-RD-Briefing-77-6-agencies.pdf
2European Citizens Perception Survey
IMPACT OF COVID-19
The biopharmaceutical industry is viewed more favourably since the start of the pandemic.
3European Citizens Perception Survey
Overall, the industry is viewed more favourably since the start of the pandemic
NETHERLANDS
BULGARIA
PORTUGAL
SLOVENIA
ROMANIA
IRELAND
GERMANY
BELGIUM
CZECHIA
HUNGARY
FRANCE
POLAND
SPAIN
ITALY
Much more favourable 5% 3% 3% 1%
5% 3%
7% 4% 3%
4% 5% 6% 4% 4%
7% 6% 10% 4% 6% 9% 8% 6%
7% 4% 11% 9% 9%
11% 9% 9% 13% 9% 18%
10% 13% 14% 16% 12%
Slightly more favourable 13% 12%
17%
16%
30% 40%
Stayed the same 35%
38%
45%
41% 46%
40% 40%
39% 47% 48% 51%
Slightly more unfavourable 41%
28%
31% 29%
25% 26% 23%
Much more unfavourable 24% 24% 24%
20%
20% 20% 20%
14%
19% 14% 14% 13% 12% 13%
10% 10% 9% 9% 6% 6%
Don’t know 6% 5%
Net: More favourable
48% 44% 43% 38% 38% 36% 34% 34% 33% 29% 26% 26% 25% 20%
18% 17% 15% 23% 13% 20% 13% 22% 23% 28% 22% 20% 20% 35%
Net: More unfavourable
The reputation of biopharmaceutical companies has improved amongst 1 in 3 adults as a result of their response to the pandemic. This has likely been due to the role
biopharmaceutical companies have played in developing COVID-19 vaccines and treatments, as well as an increased appreciation of the role of the healthcare system in society
more generally. However, the shift has not been entirely positive, with about 1 in 5 respondents reporting to be less favourable towards the industry.
Slovenia is the only country in which attitudes have shifted more negatively than positively, with 35% of people reporting to be more unfavourable and only 20% reporting as
more favourable. The most positive shifts were in Bulgaria and Spain, where 47% and 44% are more favourable, versus 18% and 17% less favourable, respectively. Large positive
shifts are also reported in Portugal, Romania and Ireland.
4European Citizens Perception Survey
RESEARCH & DEVELOPMENT IN THE BIOPHARMACEUTICAL INDUSTRY
Europeans surveyed were 2-4 times more likely to correctly answer that the biopharmaceutical industry invests the largest percentage of its income in R&D, compared with
any other industry in the EU. Though the biopharmaceutical industry was the most popular answer, an overall majority still assume that it is another industry that invests most.
Although the drive for vaccine and treatment research and authorisation in response to the coronavirus pandemic has made certain aspects of the R&D process better
understood, misconceptions remain prevalent. Such misconceptions may impact the perceived value that the biopharmaceutical industry brings and how this translates into
fair and sustainable pricing.
5European Citizens Perception Survey
The cost of developing a medicine is not well understood
Most Europeans do not know how much it costs to develop a medicine, with many Perceived average cost of developing a new medicine - by country
believing it is considerably cheaper than the reality.
The correct average cost of developing a new medicine is €1.9 billion.³
NETHERLANDS
Less than 10% of respondents believe it costs over €1 billion to develop a
medicine. More respondents believe it costs less than €10 million to develop a
BULGARIA
SLOVENIA
PORTUGAL
medicine. People in Romania and Bulgaria are the most likely to say it costs more
ROMANIA
HUNGARY
CZECHIA
IRELAND
GERMANY
BELGIUM
than €1 billion (16% and 14%, respectively). Along with Poland and Slovenia, these
POLAND
FRANCE
ITALY
SPAIN
were the only countries in which more than 10% of respondents estimated
correctly.
Compared to the 2019 Survey, respondents are less likely to believe it costs more
than €1 billion to develop a medicine (9% in the 2019 Survey versus 5% now).
19% 26% 13% 23% 20% 27% 17% 17% 14% 22% 19% 29% 21% 25%
11% 5%
Pre-clinical 7% 7% 23% 5%
Drug discovery 16% 27% 9% 5%
Clinical trials 11% 24% 23% 21% 4%
testing 14% 22% 4%
18% 4% 18%
19% 20% 8% 14%
42% 22%
17% 20%
36% 36% 41% 41%
39% 43%
37% 43%
30% 35%
21% 33%
Approval Medicine becomes €1.9 31%
for market available for patients
billion
15% 22% 11% 16% 17% 12% 16% 12% 15% 13% 14% 11% 13% 14%
The R&D of medicines in the biopharmaceutical industry is a long and
resource-intensive process. It starts with drug discovery and goes through three
phases – pre-clinical development, clinical trials, and registration and authorization
– before a medicine can become available to patients.
Under €10 million €10 million - €100 million Don’t know
3. Di Masi et al. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016.
€100,000,001 - €1 billion €1 billion+
DOI: 10.1016/j.jhealeco.2016.01.012
6European Citizens Perception Survey
Understanding of relative R&D spend is improving
The majority of Europeans surveyed are not aware that the biopharmaceutical industry is the largest spender on R&D in the EU by proportion of income,4 but there are signs that
this understanding is improving.
% who believe this industry spends the highest proportion of revenue on R&D % who believe the biopharmaceutical industry spends the highest proportion of
revenue on R&D
IRELAND
PORTUGAL
SLOVENIA
HUNGARY
BULGARIA
SPAIN
CZECHIA
ITALY
BELGIUM
POLAND
NETHERLANDS
GERMANY
ROMANIA
FRANCE
Pharmaceutical and biotechnology - 38%
Aerospace & defence - 14%
Software and computer services - 12%
Technology hardware and electrical equipment - 10%
Automotive - 9%
48% 47% 43% 42% 41% 38% 38% 37% 37% 35% 34% 31% 30% 26%
Don’t know - 17%
43% 23% 26% 31% 20% 21%
Almost 40% of respondents think that the biopharmaceutical industry spends the
largest percentage of its income on R&D in the EU. This is 2-4 times higher than 2020 2019
other tested industries.
Compared to the previous survey, a higher proportion of respondents in countries
included in the 2019 Survey (+11p.p.) correctly believe that the biopharmaceutical Between European countries, there are significantly different perceptions of R&D
industry spends more on R&D in the EU than any other industry. spend. Nearly half of respondents in Ireland and Portugal say that the
biopharmaceutical industry spends the largest percentage of its income on R&D.
In comparison, just over a quarter of those in France say the same.
4. Mafini et al (European Commission, Joint Research Centre). The 2020 EU industrial R&D investment scoreboard. 2020.
DOI: 10.2760/203793
7European Citizens Perception Survey
Europeans underestimate the time it takes to develop a medicine
Perceived average length of time to develop a new medicine
Just 7% of Europeans can correctly estimate the length of time it takes to develop - by country
a medicine.
The average time it takes is 12-13 years.5
NETHERLANDS
A majority of respondents believe it takes less than five years. Respondents in the
BULGARIA
PORTUGAL
SLOVENIA
Netherlands and Hungary were most likely to estimate correctly that it takes 10-12
ROMANIA
GERMANY
HUNGARY
BELGIUM
IRELAND
CZECHIA
years (both 14%) followed by Czechia, Ireland and Belgium (13%, 12% and 11%,
POLAND
FRANCE
ITALY
SPAIN
respectively). In all other countries, 10% or less estimated correctly.
Pre-clinical
Drug discovery Clinical trials
testing 4% 5% 10% 8% 6% 7% 3% 12% 10% 6% 10% 6% 7% 6%
1% 2% 1% 2% 2% 2%
2% 1% 2% 1% 4% 4%
4% 6% 5% 8% 9% 3% 12%
7% 8% 10% 10% 14%
18% 11% 14% 13%
17% 24% 33%
17% 27% 24% 28% 30%
21% 29% 25% 32%
73% 71% 29%
68%
60%
Approval Medicine becomes 58% 58%
12-13
for market available for patients 55% 54% 52% 51% 51%
Years 50% 47% 46%
In the 2019 Survey, 16% of respondents correctly estimated the length of time it
takes to develop a medicine, compared with 7% now. This suggests expectations
have been strongly influenced by the speed of development of COVID-19 vaccines
and treatments.
Net: 0-5 years Net: 5-10 years Don’t know
The fact that vaccines and treatments were developed so quickly is an Net: 10-20 years Net: 20+ years
extraordinary achievement. However, many factors contributed to the uniqueness
of the situation, including strong worldwide collaboration and mobilisation of
resources, years of previous research on related viruses, use of pre-existing
5. Di Masi et al. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016.
vaccine technology, and emergency authorisation processes. DOI:10.1016/j.jhealeco.2016.01.012
8European Citizens Perception Survey
Europeans overestimate clinical trials success Europeans underestimate how many APIs originate in the EU
On average, respondents say that 33% of medicines that enter the clinical trials More than three quarters of Active Pharmaceutical Ingredients (APIs) for new
stage are successfully made available for patients. In reality, the figure is 10%.6 medicines are developed in the EU.7 Respondents estimated this figure to be just
over one third.
Pre-clinical
Drug discovery
testing
Actual share 77%
Clinical Approval
trials for market
10%
90% Medicine becomes
Estimated share 37%
available for patients
Respondents in Slovenia were the most likely to correctly estimate that 1-24% of People in Romania were the most likely to guess it was over 75%, and people in
medicines successfully make it through clinical trials (40%). People in France were Slovenia were the least likely (11% and 3%, respectively). 18% of all respondents did
the least likely (26%). not feel able to make an estimate.
6. Di Masi et al. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016. 7. European Federation of Pharmaceutical Industries. Internal survey (n=17). 2020.
DOI: 10.1016/j.jhealeco.2016.01.012
9European Citizens Perception Survey
ACCESS TO MEDICINES
In general, Europeans surveyed were twice as likely to believe the US was the fastest market for medicines approval. In 2019,
the timeframe for the EMA to approve a new active substance was a median of 423 days versus 243 days in the USA.
Respondents were more likely to be pessimistic than optimistic about their own country’s speed and level of access, in
comparison with other EU countries, and more than half of respondents would prioritise faster access to medicines, even if
that meant higher purchase costs.
Access to medicines is a topic of critical importance to many Europeans, and one of particular interest in light of the ongoing
rapid development, procurement and distribution of vaccines to combat the coronavirus pandemic. We share the goals of
addressing barriers and delays to access to innovative medicines for patients, and bringing all stakeholders together to deliver
equal access in Europe.
10European Citizens Perception Survey
Opinions differ on the relative availability of medicines
Survey respondents are more likely to be pessimistic than optimistic about the speed of access and availability of medicines in their country compared to the rest of the EU.
Net: More Medicines 19% Net: Fewer Medicines 30%*
About the same Don’t know
8% 11% 44% 8% 11% 18%
8% 11% 42% 7% 11% 20%
About the same Don’t know
Net: Faster Access 19% Net: Slower Access 32%*
Much more / Much faster More / Faster About the same Don’t know Fewer / Slower Much fewer / Much slower
*Net figures higher than totals of individual figures due to rounding
About 1 in 3 respondents think that fewer medicines are available in their country, and that medicines become available more slowly in their country, when compared with the
rest of the EU. There is significant divergence of perspective on this topic between the countries surveyed.
Respondents from Bulgaria, Poland and Romania were the most likely to report that they perceived access to medicines to be slower and more limited in their country, in
relation to other EU countries. Those in Germany, the Netherlands and France were most likely to believe the level and speed of access to be better in their country. These
perceptions are consistent with the assessment of medicines availability compared with the EU average in the EFPIA Patients W.A.I.T. Indicator Survey, which highlighted a clear
disparity between countries in terms of both the speed of access to - and level of availability of - EMA approved medicines. For example, the time to availability for Germany and
Denmark was 120 days and 169 days respectively, compared to 815 days and 883 days in Poland and Romania. Similarly, nearly 90% of medicines are available in Germany and
Denmark, with this figure being just over a quarter in Poland and Romania.8
Comparing these results with the 2019 Survey shows a significantly improved perspective in the countries analysed in that survey (Belgium, France, Germany, Ireland, Italy and
Spain) with regard to the level and speed of medicines access.
8. European Federation of Pharmaceutical Industries. EFPIA Patients W.A.I.T. Indicator 2020 Survey. URL: https://www.efpia.eu/media/602652/efpia-patient-wait-indicator-final-250521.pdf
11European Citizens Perception Survey
Almost one in three Europeans surveyed think fewer medicines are available in their country compared to
the rest of the EU Don’t
know
30%
8%
17% 34%
27%
13% More
29% 18% 11% 19%
51%
13%
About
the same
44% Fewer
29%
14%
30% 26%
12% Total: all countries
9%
39%
23%
13%
17%
36%
12%
10%
57%
25% 8%
58%
19%
20% Net: More Medicines
Net: Fewer Medicines
12European Citizens Perception Survey
Almost one in three Europeans surveyed believe access to medicines to their own country is slower than in
the rest of the EU Don’t
know
20% 31% 28% 7%
13% Faster
24%
31% 17% 13% 19%
61%
16%
About
the same
43% Slower
31%
14%
26% 25%
12% Total: all countries
11%
35%
24%
12%
22%
34%
16%
14%
50%
36% 9%
59%
22%
24% Net: Faster Access
Net: Slower Access
13European Citizens Perception Survey
Europeans prioritise the speed of access to medicines Europeans value patent protection
More than half of respondents in surveyed countries would prioritise faster access Europeans surveyed overwhelmingly recognised patent protection of unique ideas
to medicine in the first year after its development, even if that means purchase as an important force in driving scientific discovery.
costs are higher.
Priorities in the first year after a new medicine is created The perceived importance of patent protection in scientific discovery
3% 6%
11%
Faster access, even if prices are Very important
higher for the first year
Fairly important
5%
Neither important nor unimportant
Lower prices, even it means
Not very important
delayed access to the medicine 35%
for some EU citizens Not at all important 15%
34% 55% Don’t know
Don’t know
Net: Important Net: Unimportant* 35%
70% 9%
*Net figure higher than total of individual figures due to rounding
14European Citizens Perception Survey
HEALTH PRIORITIES
When asked which diseases the EU should consider a priority in health in the coming years, Europeans surveyed identified cancer as their top priority, followed by
cardiovascular disease and respiratory diseases.
This is in line with the current priorities of the European Commission, who in February 2021 launched Europe's Beating Cancer plan. However, other diseases impacting large
numbers of Europeans, such as diabetes, remain quite low on the list of priorities of European citizens.
Please note: The questions in this section were carried over from the 2019 Survey so the results could be compared. Therefore, the results do not directly reflect COVID-19 as a
standalone illness. The impact of the pandemic is examined in a separate section.
15European Citizens Perception Survey
Cancer, cardiovascular and respiratory disease are Europeans’ top health priorities
Priorities for the next five years
Ranked 1st
33%
Cancer
61%
Ranked in the top 3
Cardiovascular 13%
(heart) disease 49%
Respiratory disease and 16%
lung disease 43%
Mental health 13%
36%
Alzheimer’s disease and 7%
dementia 27%
6%
Diabetes
22%
Liver, kidney and 2% Adults in the surveyed countries identified cancer, cardiovascular disease, and
digestive diseases 16% respiratory and lung diseases as the top 3 illnesses for the EU to focus on over the
next five years. One in three respondents ranked cancer as the biggest priority.
4%
HIV / AIDS 13%
Only 6% ranked diabetes as the top priority and less than one quarter placed it in
2% their top 3. This is despite the fact that 60 million people in Europe have diabetes,
Other presenting a significant challenge for European health systems, which spend €150
2%
billion on the disease.9
4%
Don’t know 4%
9. International Diabetes Federation. International Diabetes Federation Atlas, 9th edition. 2019.
URL:https://www.diabetesatlas.org/en/
16European Citizens Perception Survey
Change from 2019 Survey
In the 2020 Survey, respiratory diseases and lung disease, which were not a top 3 priority in the last survey, have risen to second place. This is perhaps unsurprising given the
focus on respiratory illness brought about by the pandemic. Alzheimer’s disease and dementia has fallen out of the top 3 to fifth priority, while 11p.p. fewer respondents
identified it as a top 3 priority. Note: the data below represents only that of the six countries which can be compared with 2020 because they featured in the 2019 Survey
(Belgium, France Germany, Ireland, Italy and Spain).
Percentage point change in priority
Cancer Alzheimer’s disease HIV / AIDS
and dementia -3p.p
-8p.p -6p.p
-10p.p -11p.p
+21p.p
+12p.p
Respiratory disease and +2p.p +3p.p Liver, kidney and
Mental health
lung disease digestive diseases -2p.p
+6p.p
Cardiovascular Diabetes +1p.p
(heart) disease Other
-6p.p -1p.p
2019: ranked 1st 2020: ranked 1st
2019: ranked in the top 3 2020: ranked in the top 3
17European Citizens Perception Survey
DIGITAL HEALTH
Health
data
Most Europeans surveyed remain open to providing health data to support digital
innovation in healthcare, but there is a trend towards less comfort in doing so.
This negative trend is a cause for concern if the EU intends to fulfil its ambitions in
digital health and health innovation.
18European Citizens Perception Survey
Europeans remain comfortable sharing data for health innovation
Most Europeans remain open to providing health data to support digital innovation in healthcare, but there is a trend towards less comfort in doing so. Overall, 26% of respondents
reported feeling uncomfortable about sharing anonymous health data in exchange for using innovations in digital healthcare, while 65% said they would be comfortable doing so.
Providing health data anonymously in exchange for using innovations in digital healthcare.
NETHERLANDS
2020 Survey results by country Comparing results from 2019 Survey markets with the 2020 Survey
BULGARIA
PORTUGAL
SLOVENIA
ROMANIA
IRELAND
CZECHIA
GERMANY
BELGIUM
HUNGARY
POLAND
FRANCE
Net: Uncomfortable 18% Net: Comfortable 68%
ITALY
SPAIN
2019 5% 13% 13% 49% 20%
5% 9% 7% 7% 10% 7% 8% 9% 8% 13% 11% 11% 9% 14%
5% 2020 8% 19% 10% 45% 18%
5% 4% 5% 8% 9%
15% 6% 8% 9% 7%
18% 17% 8% 14%
14% 9% 12% Net: Uncomfortable 27%
16% 16% 19% 21% 28% Net: Comfortable 63%
17% 18% 22%
43% 52% 16% 23%
51% 51%
44% 49% 44% 46%
47% 42% 43%
40%
44% 37%
31%
21% 20% 20% 20% 23%
19% 19% 18% 18%
16% 16% 15%
10%
Net: Comfortable
74% 73% 71% 71% 68% 68% 67% 64% 63% 60% 59% 59% 54% 52%
20% 18% 23% 22% 22% 25% 25% 26% 29% 27% 30% 30% 37% 35%
Net: Uncomfortable
Respondents in Hungary and France are the most likely to be uncomfortable with While positive overall, results from the 2020 Survey indicate Europeans are
exchanging health data for innovations (37% and 35%, respectively). People in becoming less comfortable with the idea of sharing data for health purposes over
Bulgaria, Poland and Italy would be the most comfortable of all tested countries with time. If Europe is to push ahead with a digital health agenda, this trend needs to be
trading their health data (74%, 73% and 71%, respectively). reversed.
19European Citizens Perception Survey
ENVIRONMENTAL EFFORTS
Europeans identify the biopharmaceutical industry as a top performer in
environmental efforts.
The areas survey respondents identified for action in the future are plastics
reduction and recycling, water conservation/reduction, and disposal of
unused/expired medicines.
PLASTICS
REDUCTION AND
RECYCLING
WATER
CONSERVATION/
REDUCTION
DISPOSAL OF
UNUSED/EXPIRED
MEDICINES
20European Citizens Perception Survey
Industry comparison Priorities
Respondents believe the top 3 future environmental efforts for the biopharmaceutical
About one in five Agriculture, forestry 21% industry should be plastics reduction and recycling, energy reduction, and disposal of
Europeans place the and fishing 40% unused/expired medicines.
biopharmaceutical
industry among their top 3 Energy and 13%
utilities 36%
performing industries for
green/environmental Plastics reduction 22%
IT, technology and 9%
efforts. 6% place it first. communications 28% and recycling efforts 57%
Healthcare 8% 14%
and social care Renewable energy
28% and energy reduction 42%
6%
Biopharmaceutical
22% Disposal of unused 17%
or expired medicines 41%
4% in general
Retail
15%
16%
Financial 5% Water conservation
39%
services 18%
5% Reducing carbon 10%
Automotive
32% of people in Portugal 14% footprint 31%
ranked the Transportation 4%
biopharmaceutical and travel 14% Getting value/supply 8%
industry in the top 3 – the chain to be greener 26%
3%
most of any country Construction
11%
surveyed. The least was
in the Netherlands, where 3% Design of products, 7%
Manufacturing processes and packaging 24%
11% ranked it in the top 3. 11%
Wholesale
2%
9% Other
1%
1%
1st Mining and 1% 1st
quarrying 6%
Ranked in the top 3 Ranked in the top 3
21European Citizens Perception Survey
LILLY IN EUROPE METHODOLOGY
Lilly is a biopharmaceutical company with over 34,000 employees worldwide, Lilly commissioned Savanta ComRes to survey 7,604 members of the general public
including more than 9,000 in Europe. Founded over 140 years ago in the United Sates across 14 European countries through an online survey.
and established in Europe in 1934, our pioneering medical breakthroughs through the
years include the first commercially available human insulin and the polio vaccine. Countries include Germany (515), France (563), Italy (588), Spain (588), Republic of
Ireland (513), Belgium (520), Netherlands (514), Poland (604), Czechia (531), Hungary
Lilly’s commercial activities span the whole of Europe, and in addition, we have a (522), Portugal (517), Slovenia (574), Romania (535) and Bulgaria (520).
considerable R&D and manufacturing presence located across four countries in
Europe. Our researchers are currently seeking breakthrough therapies in Diabetes, Fieldwork took place between 2nd September and 6th October 2020.
Oncology, Immunology, Neurodegeneration and Pain. Lilly is also bringing the full
force of our scientific and medical expertise to attack the coronavirus pandemic Data were weighted to be demographically representative of all adults ages 18+ in
around the world. each country by age, gender and region.
To learn more about Lilly in Europe, please visit us at www.LillyEU.com.
22European Citizens Perception Survey
You can also read
